Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2011.123 | Use of the Montreal Cognitive Assessment vs the Mini-Mental State Examination to screen for cognitive impairment in Chinese anaeurysmal subarachoid hemorrhage patients | Prof. WONG George Kwok Chu |
| 2009.301 | Cerebral glucose metabolism after acute aneurysmal subarachnoid haemorrhage | Prof. Wong George Kwok Chu |
| 2011.097 | Cognitive dysfunction and delayed cerebral infarction in Chinese aneurysmal subarachnoid hemorrhage patients | Prof. WONG George Kwok Chu |
| 2020.202 | Development and Validation of a Clinical Risk Score Model for Intracranial Aneurysm Screening in Ischemic Stroke Patients |
Prof. WONG George Kwok Chu 黃國柱 |
| 2020.204 | Establishment and characterization of meningioma patient-derived organoids |
Prof. WONG George Kwok Chu 黃國柱 |
| 2018.291 | Assessment of the Impact of Ultra-Early Aneurysm Treatment on Outcomes in Patients with Poor Neurological Status after Intracranial Aneurysm Rupture |
Prof. WONG George Kwok Chu 黃國柱 |
| 2014.157 | Selective Serotonin Reuptake Inhibitor to improve cognitive function after aneurysmal subarachnoid hemorrhage | Prof. WONG George Kwok Chu |
| 2022.291 | Adjunctive embolization for chronic subdural hematoma at high risk of recurrence: A Phase I RCT (Embo-Subdu I) | Prof. WONG George Kwok Chu |
| 2020.627 | Intracranial aneurysms in ischemic stroke patients: a retrospective review |
Prof. WONG George Kwok Chu 黃國柱 |
| 2023.035 | Machine-learning Method for Retinal Image Analysis to Detect Intracranial Aneurysms | Prof. WONG George Kwok Chu |
| 2021.288 | Prospective Audit of Intracranial Aneurysm Stent Treatment | Prof. WONG George Kwok Chu |
| 2022.116 | Long term outcome of aneurysms treated with flow diverters: multi-center retrospective study | Prof. WONG George Kwok Chu |
| 2021.390 | Impact of Ultra-Early Aneurysm Treatment on outcomes in Patients with Poor Neurological Status after Intracranial Aneurysm Rupture: a retrospective review |
Prof. WONG George Kwok Chu 黃國柱 |
| 2022.666 | Mobile application development for impact assessment of patients after subarachnoid haemorrhage | Prof. WONG George Kwok Chu |
| 2010.075 | Prediction of Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Haemorrhage using Transient Hyperemic Response Test and Implications on Length of Hospitalization | Prof. Wong George Kwok-chu |
| 2007.436 | Co-Operative Study on Brain Injury Depolarisations (COSBID): (Traumatic and Ischaemic Injury to the Human Brain) | Dr. Wong George Kwok-chu |
| 2008.076 | Disability in Young People and Adults One Year after Head Injury: Impact, Causes and Factors | Dr. Wong George Kwok-chu |
| 2008.073 | Computed Tomography Antiography and Venography in Place of Catheter Angiography for Acute Spontaneous Non-Hypertensive Intracerebral Haemorrhage | Dr. Wong George Kwok-chu |
| 2024.460 | A Phase 2b, multi-centre, randomized, partially placebo-controlled, double-blind study to investigate the safety and efficacy of sequential therapy with daplusiran/tomligisiran followed by bepirovirsen in participants with chronic hepatitis B virus on background nucleos(t)ide analogue therapy (B-United) | Prof. WONG Grace |
| 2025.597 | Construction of diagnostic and predictive models for cirrhosis patients with complications of liver disease | Prof. Wong Grace |
| 2024.007 | Secular trend of chronic liver diseases - a retrospective observational cohort study | Prof. WONG Grace |
| 2023.312 | An Open-Label Phase 1b Study Evaluating the Safety, Tolerability, Immunogenicity and Antiviral Activity of Multiple Doses of CLB-3000 in Subjects with Chronic Hepatitis B | Prof. WONG Grace |
| 2021.291 | The setting up of Geriatric Diabetes Programme in a regional hospital of Hong Kong | Dr. WONG Grace Hiu Yan |
| 2020.615 | Evaluation of AFP, AFP-L3, PIVKA-II and GALAD Score (Gender, Age, AFP-L3, AFP, DCP/PIVKA-II) for risk assessment of Hepatocellular Carcinoma (HCC) | Prof. WONG Grace Lai Hung |
| 2022.653 | A Phase 1/2a, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Healthy Volunteers and in Subjects with Chronic Hepatitis B Infection, Including Subjects with Chronic Hepatitis D Infection | Prof. WONG Grace Lai Hung |
| 2021.239 | Retrospective cohort study for early detection of new-onset chronic diseases in recovered COVID-19 patients using population-based datasets | Prof. WONG Grace Lai Hung |
| 2023.265 | A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB) |
Prof. WONG Grace Lai Hung Lai Hung Wong |
| 2020.459 | Elimination of chronic hepatitis B in Hong Kong – to meet the WHO goals |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2023.151 | A phase 2b, open-label study to evaluate the efficacy, safety, tolerability, immunogenicity and treatment regimens of VTP-300 combined with low-dose nivolumab in Chronic Hepatitis B Infection |
Prof. WONG Grace Lai Hung Grace LH Wong |
| 2021.223 | Drug-Drug Interactions in Patients Treated with DAAs in Hong Kong | Prof. WONG Grace Lai Hung |
| 2022.601 | Real-World Data to Assess HCV Patients Treated with SOF/VEL without RBV |
Prof. Wong Grace Lai Hung 黃麗虹教授 |
| 2022.552 | Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well 1) |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2021.427 | A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) |
Prof. WONG Grace Lai Hung 黃麗虹教授 |
| 2023.273 | A PHASE I STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7565020 IN HEALTHY PARTICIPANTS AND IN PARTICIPANTS WITH CHRONIC HEPATITIS B VIRUS INFECTION | Prof. WONG Grace Lai Hung |
| 2023.200 | A Phase 1, Double-Blind, Randomized, Placebo-Controlled, First-in-Human Study of Orally Administered ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single-Ascending Doses (Part 1) and Multiple-Ascending Doses in Healthy Volunteers (Part 2), and Multiple Doses in Subjects with Chronic Hepatitis B (Part 3) |
Prof. WONG Grace Lai Hung Grace LH Wong |
| 2023.268 | A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and Pegylated Interferon Alpha (PEG-IFNα) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection | Prof. WONG Grace Lai Hung |
| 2021.297 | A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNa in Subjects with Chronic Hepatitis B Virus Infection |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2022.676 | A Phase 2 Study Evaluating the Efficacy and Safety of VIR-3434 and/or VIR-2218 Containing Regimens in HBeAg-negative Participants with Low Viral Burden of Chronic Hepatitis B Infection (THRIVE) | Prof. WONG Grace Lai Hung |
| 2022.480 | A PHASE II, RANDOMISED, ADAPTIVE, OPEN-LABEL PLATFORM TRIAL TO EVALUATE EFFICACY AND SAFETY OF MULTIPLE COMBINATION THERAPIES IN PARTICIPANTS WITH CHRONIC HEPATITIS B |
Prof. WONG Grace Lai Hung 黃麗虹教授 |
| 2022.678 | A Phase 2 Study Evaluating the Efficacy and Safety of VIR-3434 and/or VIR-2218 Containing Regimens in Participants with Chronic Hepatitis B Infection (STRIVE) | Prof. WONG Grace Lai Hung |
| 2023.344 | A Phase 1/2 Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BW-20507 in Healthy Subjects, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Subjects with Chronic HBV Infection and a Long-term Study to Evaluate the Safety, Tolerability, and Efficacy of BW-20507 with/without HEPLISAV-B® in Subjects with Chronic HBV Infection | Prof. WONG Grace Lai Hung |
| 2022.509 | Sodium-glucose co-transporter-2 inhibitor (SGLT2i) to prevent of liver complications in patients with chronic hepatitis B and diabetes mellitus: a double-blind, randomised, placebo-controlled trial |
Prof. WONG Grace Lai Hung 黃麗虹教授 |
| 2020.544 | Deep learning of combined clinical data and CT images in patients with chronic viral hepatitis – risk prediction and complication reduction to facilitate eliminating viral hepatitis by year 2030 |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2021.106 | Prospective evaluation of a fast-track treatment pathway for patients with chronic hepatitis B under primary care |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2020.509 | A Phase 2a, Multicenter, Single-Blind, Placebo-Controlled, Multiple Cohort Study Evaluating ABI-H2158-Containing Regimens in Chronic Hepatitis B Infection |
Prof Wong Grace Lai Hung 黃麗虹 |
| 2021.112 | A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection | Prof. WONG Grace Lai Hung |
| 2021.091 | Comparative Risk of HCC in CHB Patients Receiving ETV or TDF-based Treatment: IPD Meta-Analysis Protocol |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2021.517 | A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects with Chronic Hepatitis B Infection |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2023.039 | A Phase 1b Multi-Center, Open-Label, Dose-Escalation, Prime and Boost Vaccination Evaluation of Two Chimpanzee Adenoviral Vectors in Adult Participants With Chronic HBV Infection Who Are Currently Receiving HBV Nucleos(t)ide Reverse Transcriptase Inhibitors | Prof. WONG Grace Lai Hung |
| 2022.324 | Chronic kidney disease progression in chronic hepatitis B patients on tenofovir alafenamide (TAF) versus entecavir |
Prof. WONG Grace Lai Hung 黃麗虹 |
Page 248 of 289.